Zydus Cadila gets FDA OK for generic Lamictal

Sandra Levy
Senior Editor
Sandra Levy profile picture

Patients with certain types of seizures have a new generic treatment option.

The Food and Drug Administration has cleared Zydus Cadila’s lamotrigine extended release tablets in dosage strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg.

The product is the generic of GlaxoSmithKline's Lamictal XR.

It will be manufactured  at the group’s manufacturing facility at SEZ, Ahmedabad.